Abstract
Bone turnover markers (BTM) are highly responsive to initiation and changes in anti-osteoporotic therapy. In contrast to the slow treatment-induced changes in bone mineral density, the fast changes in BTM enable the clinician to adjust treatment management within a short timeframe. This review describes how BTM can be used for treatment monitoring, including monitoring during discontinuation of alendronate and denosumab therapy. In addition, sources of errors and pitfalls when using BTM monitoring will be described.
| Translated title of the contribution | Clinical application of bone turnover markers in osteoporosis |
|---|---|
| Original language | Danish |
| Article number | V07230432 |
| Journal | Ugeskrift for Laeger |
| Volume | 186 |
| Issue number | 5 |
| ISSN | 0041-5782 |
| DOIs | |
| Publication status | Published - 29 Jan 2024 |
Fingerprint
Dive into the research topics of 'Clinical application of bone turnover markers in osteoporosis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS